August 24, 2026

Hanmi-Genentech $2.3B UCN2 Obesity Deal, Gilead Trodelvy+Keytruda EU Authorization, Barclays M&A Reopens, Capricor CRL

Hanmi-Genentech $190M+$2.3B deal for UCN2 obesity peptide HM17321. Gilead Trodelvy+Keytruda EU. Barclays M&A reopens. Capricor deramiocel CRL.

4 stories · Covering industry, regulatory

Editor's Note

Monday's peptide news is anchored on the Hanmi Pharm and Genentech (Roche Group) exclusive licensing agreement for HM17321, a proprietary urocortin-2 (UCN2) analog peptide for obesity that selectively activates the corticotropin-releasing factor 2 receptor (CRFR2), a mechanism distinct from the incretin pathway that anchors every currently-approved obesity drug. Deal terms: $190 million upfront payment plus up to $2.3 billion in development, regulatory, and commercial milestone payments, plus tiered royalties on sales. HM17321 is positioned as a potential first-in-class treatment designed to simultaneously promote weight loss and preserve lean body mass, a differentiated profile against the semaglutide-tirzepatide-retatrutide GLP-1 class that produces roughly 25% muscle loss in the total weight lost. In November 2025, Hanmi received FDA IND clearance to initiate a Phase 1 clinical trial; Hanmi is responsible for completing Phase 1, after which Genentech takes over from Phase 2 forward. Gilead Sciences (NASDAQ: GILD) received European Commission marketing authorization for Trodelvy (sacituzumab govitecan-hziy, an anti-Trop-2 antibody-drug conjugate) in combination with Keytruda for first-line PD-L1-positive metastatic triple-negative breast cancer, positioning as the first ADC-plus-immunotherapy combination approved in first-line metastatic TNBC in the EU. Barclays' Head of US Biopharma Equity Research Emily Field told CNBC Monday that the biotech M&A freeze is over, with capital markets reopening, large-cap pharma buyers committing to more deals, and fresh oncology data extending the value proposition beyond weight-loss drugs. And Capricor Therapeutics (NASDAQ: CAPR) faced its PDUFA target action date Saturday August 22 for deramiocel in Duchenne muscular dystrophy cardiomyopathy following the July 29 FDA advisory committee 9-3 vote against approval, with a Complete Response Letter the expected outcome.

Industry

Hanmi Pharm (KRX: 128940) Signed Monday August 24, 2026 an Exclusive Licensing Agreement With Genentech (a Member of the Roche Group) for HM17321, a Proprietary Urocortin-2 (UCN2) Analog Peptide for Obesity That Selectively Activates the Corticotropin-Releasing Factor 2 Receptor (CRFR2), a Mechanism Distinct From the Incretin Pathway Anchoring Every Currently-Approved Obesity Drug (Semaglutide, Tirzepatide, Orforglipron, and the Broader GLP-1 Class); Deal Terms: $190 Million Upfront Payment Plus Up to $2.3 Billion in Development, Regulatory, and Commercial Milestone Payments, Plus Tiered Royalties on Sales; HM17321 Is Positioned as a Potential First-in-Class Treatment Designed to Simultaneously Promote Weight Loss and Preserve Lean Body Mass; Hanmi Received FDA IND Clearance in November 2025 to Initiate a Phase 1 Clinical Trial and Retains Rights in South Korea; Genentech Takes Over From Phase 2 Forward

Hanmi Pharm (KRX: 128940) signed Monday August 24, 2026 an exclusive licensing agreement with Genentech (a member of the Roche Group) for HM17321, a proprietary urocortin-2 (UCN2) analog peptide for obesity. Deal terms: $190 million upfront payment, up to $2.3 billion in development, regulatory, and commercial milestone payments, plus tiered royalties on sales. Territory: Genentech secures global rights excluding South Korea, where Hanmi retains the license. Mechanism: HM17321 selectively activates the corticotropin-releasing factor 2 receptor (CRFR2), a peptide-hormone receptor pathway distinct from the incretin pathway (GLP-1 receptor, GIP receptor) that anchors every currently-approved obesity drug including semaglutide, tirzepatide, orforglipron, and the broader GLP-1 receptor agonist class. Urocortin-2 is a naturally occurring 38-amino-acid peptide of the corticotropin-releasing factor family. Differentiated profile: HM17321 is positioned as a potential first-in-class treatment designed to simultaneously promote weight loss and preserve lean body mass, an important differentiator against the semaglutide-tirzepatide-retatrutide GLP-1 class where roughly 25% of the total weight lost is lean muscle mass. Development pathway: Hanmi received FDA IND clearance to initiate a Phase 1 clinical trial in November 2025. Hanmi is responsible for completing the Phase 1 clinical trial, after which Genentech will take over development starting with Phase 2 clinical trials. The deal represents one of the largest 2026 obesity licensing transactions and adds a substantially different mechanism to Roche's obesity portfolio that also includes CT-388 (dual GIP/GLP-1 agonist from the Carmot Therapeutics acquisition).

#hanmi-pharm #genentech #roche #hm17321 #ucn2 #urocortin-2 #crfr2-receptor #obesity #non-glp-1-mechanism #190-million-upfront #2-3-billion-milestones #muscle-preservation #ct-388 #carmot-therapeutics

Regulatory

Gilead Sciences (NASDAQ: GILD) Received European Commission Marketing Authorization Monday August 24, 2026 for Trodelvy (Sacituzumab Govitecan-Hziy, an Anti-Trop-2 Antibody-Drug Conjugate Delivering the SN-38 Topoisomerase I Inhibitor Payload) in Combination With Keytruda (Pembrolizumab) for First-Line Treatment of Adults With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) With PD-L1 CPS ≥10 and No Prior Systemic Therapy for Metastatic Disease; Positioning as the First and Only Antibody-Drug Conjugate Plus Immunotherapy Combination Approved for First-Line Metastatic TNBC in the EU's 27 Member States Plus Norway, Iceland, and Liechtenstein; The Approval Extends Gilead's ADC Commercial Franchise and Adds to the ADC Combination-Therapy Category That Is Attracting Increasing Investment Across Oncology

Gilead Sciences (NASDAQ: GILD) received European Commission marketing authorization Monday August 24, 2026 for Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) for first-line treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). Approval criteria: PD-L1 combined positive score (CPS) ≥10 and no prior systemic therapy for metastatic disease. Trodelvy mechanism: an antibody-drug conjugate (ADC) with an anti-Trop-2 monoclonal antibody linked to the SN-38 topoisomerase I inhibitor payload; when Trop-2 (trophoblast cell surface antigen 2) is expressed on tumor cells, Trodelvy binds and internalizes to release the cytotoxic SN-38 inside the cancer cell. The Keytruda addition provides checkpoint inhibitor activity against PD-L1-positive tumors. Positioning: the first and only antibody-drug conjugate plus immunotherapy combination approved for first-line metastatic TNBC in the EU's 27 member states, plus Norway, Iceland, and Liechtenstein. The FDA had already approved the same combination in June 2026 based on the same clinical evidence. The approval extends Gilead's ADC commercial franchise. The ADC combination-therapy category (ADC + checkpoint inhibitor, ADC + targeted therapy) has attracted increasing investment across oncology as ADCs establish clinical value across breast, bladder, lung, and other solid tumors; adjacent peptide-drug conjugates (PDCs) with tumor-targeting peptides plus cytotoxic payloads are also expanding as a related modality.

#gilead-sciences #gild #trodelvy #sacituzumab-govitecan #keytruda #pembrolizumab #european-commission #eu-authorization #triple-negative-breast-cancer #tnbc #antibody-drug-conjugate #adc #anti-trop-2 #sn-38 #pd-l1

Industry

Barclays' Head of US Biopharma Equity Research Emily Field Told CNBC Monday August 24, 2026 That the Biotech Mergers and Acquisitions (M&A) Freeze Is Over, With Capital Markets Reopening, Large-Cap Pharma Buyers Committing to More Deals, and Fresh Oncology Data Extending the Sector's Value Proposition Beyond Weight-Loss Drugs; The Commentary Follows a Rapid Acceleration of Biotech M&A Activity Through August Including Samsung Biologics' Pending $1.8 Billion PolyPeptide Group Acquisition, BioMarin's Alesta Therapeutics Acquisition, Tolerance Bio's $260 Million NT-I7 License From NeoImmuneTech, LEO Pharma's Dersimelagon Acquisition From Mitsubishi Tanabe, and Hanmi Pharm's $2.3 Billion HM17321 Licensing to Genentech Announced the Same Monday

Barclays' Head of US Biopharma Equity Research Emily Field told CNBC Monday August 24, 2026 that the biotech mergers and acquisitions (M&A) freeze is over. Key drivers cited: capital markets reopening (drug startup IPOs have raised roughly $6 billion year-to-date, more than the combined total of the prior four years by this point), large-cap pharma buyers committing to more deals following a multi-year period of caution, and fresh oncology data extending the sector's value proposition beyond the weight-loss drug narrative that dominated 2024-2025. The commentary follows a rapid acceleration of biotech M&A activity through August: Samsung Biologics' pending $1.8 billion PolyPeptide Group AG all-cash tender offer (formal prospectus expected end of August), BioMarin Pharmaceutical's Alesta Therapeutics acquisition for ALE1 program (August 21), Tolerance Bio's $260 million exclusive license from NeoImmuneTech for NT-I7 (efineptakin alfa, long-acting IL-7 fusion protein, August 20), LEO Pharma's dersimelagon (MC1R agonist) acquisition from Mitsubishi Tanabe (August 18), and Hanmi Pharm's up-to-$2.3 billion HM17321 UCN2 licensing to Genentech announced the same Monday. The pattern suggests the M&A environment is now supportive for both mid-cap platform buyers (Samsung Biologics, LEO Pharma, BioMarin) and mega-cap oncology and metabolic-disease buyers (Roche/Genentech, Bristol Myers Squibb, Merck, Eli Lilly) actively pursuing deals. Field's commentary also notes that oncology data (particularly the Merck-Moderna intismeran Phase 3 melanoma win and Gilead Trodelvy+Keytruda EU authorization from the same week) has substantially reset investor expectations about the sector beyond obesity.

#biotech-ma-reopening #barclays #emily-field #biopharma-equity-research #capital-markets #samsung-biologics #polypeptide-group #biomarin #alesta-therapeutics #tolerance-bio #nt-i7 #leo-pharma #hanmi-pharm #roche-genentech #6-billion-ipos

Regulatory

Capricor Therapeutics (NASDAQ: CAPR) Faced Its Prescription Drug User Fee Act (PDUFA) Target Action Date Saturday August 22, 2026 for Deramiocel (Cardiosphere-Derived Cell Therapy, Not a Peptide) in Duchenne Muscular Dystrophy (DMD) Cardiomyopathy Following the July 29 FDA Cellular, Tissue, and Gene Therapies Advisory Committee 9-3 Vote Against Approval; A Complete Response Letter (CRL) Is the Expected Outcome (Would Mark the Second CRL for the Program After the July 2025 Initial Rejection), and CAPR Stock Slipped in Advance of the Decision on Elevated Volume as Investors Positioned for the Anticipated Regulatory Rejection Under Continued Statistical Concerns About the Phase 3 HOPE-3 Trial Left Ventricular Ejection Fraction (LVEF) Endpoint Analysis Sensitivity to Missing-Data Assumptions

Capricor Therapeutics (NASDAQ: CAPR) faced its Prescription Drug User Fee Act (PDUFA) target action date Saturday August 22, 2026 for deramiocel (a cardiosphere-derived allogeneic cell therapy, not a peptide) in Duchenne muscular dystrophy (DMD) cardiomyopathy. Background: the FDA issued a Complete Response Letter (CRL) in July 2025 citing that the Phase 2 data supporting the cell therapy fell short of the statutory requirement for substantial evidence of effectiveness. Capricor reported positive Phase 3 HOPE-3 trial results in December 2025 meeting both primary and secondary endpoints, and the FDA accepted the resubmission in March 2026 with a Class 2 resubmission classification and August 22 target action date. The July 29, 2026 FDA Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 that available evidence does not provide substantial evidence of effectiveness to recommend approval. Panel members cited concerns about the stability of the statistical results, with left ventricular ejection fraction (LVEF) endpoint outcomes appearing highly sensitive to how missing data were handled and which analytic assumptions were applied. A second Complete Response Letter is the expected outcome, and CAPR stock slipped in advance of the decision on elevated volume as investors positioned for the anticipated regulatory rejection. Duchenne muscular dystrophy affects approximately 20,000 US patients (predominantly boys with X-linked inheritance) and progressive cardiomyopathy is the leading cause of death in the DMD population. The DMD cardiomyopathy indication remains without an FDA-approved therapy. Capricor holds Rare Pediatric Disease Designation for deramiocel, which may qualify the company for a Priority Review Voucher upon eventual approval if it comes.

#capricor-therapeutics #capr #deramiocel #duchenne-muscular-dystrophy #dmd-cardiomyopathy #pdufa-action-date #hope-3 #cell-therapy #complete-response-letter #lvef-endpoint #statistical-instability #rare-pediatric-disease-designation